Authors : Dhanyashree; Dr. Viresh K Chandur

Volume/Issue : Volume 10 - 2025, Issue 4 - April

Google Scholar : https://tinyurl.com/3ur7kp4b

Scribd : https://tinyurl.com/53rjzcuw

DOI : https://doi.org/10.38124/ijisrt/25apr1435

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : The novel drug delivery system ‘spanlastics’ has received prominence for its potential to enhance drug stability, targeted delivery, and bioavailability. Unlike traditional drug carriers, these surfactant-based nanovesicles have nonionic surfactants (Spans) incorporated with edge activators, giving them high permeability and high deformability. Moreover, spanlastic formulations overcome some of the most important limitations of traditional drug delivery systems, offering higher chemical stability and biocompatibility. Their ability to encapsulate hydrophilic and lipophilic drugs increases spanlastics' use for various administration routes like oral, ocular, transdermal, and nasal delivery. Furthermore, spanlastics enable controlled and sustained drug release, decreasing the frequency of dosage and improving patient compliance. This review comprehensively analyzes spanlastic technology covering its composition, preparation methods, mechanisms of drug penetration, and characterization, as well as major pharmaceutical applications, highlighting the technology's prospects in contemporary drug delivery and nanomedicine.

Keywords : Nanovesicles; Spanlastics; Surfactants; Edge Activators; Drug Permeability.

References :

1. Alhammid SN, Kassab HJ, Hussein LS, Haiss MA, Alkufi HK. Spanlastics nanovesicles: an emerging and innovative approach for drug delivery. Maaen J Med Sci. 2023;2(3):100-7.
2. Vindhya VS, Kamath KK, Shripathy D, Shabaraya AR. Formulation of oxiconazole nitrate spanlastic gel. Int J of Pharm Sci. 2024;2(4):539-46.
3. DCruz CEM, Bhide PJ, Kumar L, Shirodkar RK. Novel nano spanlastic carrier system for buccal delivery of lacidipine. J Drug Deliv Sci Technol. 2022;68:103061.
4. Sharma A, Pahwa S, Bhati S, Kudeshia P. Spanlastics: a modern approach for nanovesicular drug delivery system. Int J Pharm Sci & Res. 2020;11(3):1057-65.
5. Chauhan MK, Verma A. Spanlatics-future of drug delivery and targeting. World J Pharm Res. 2017;6(12): 429-46.
6. Ratnam MA, Sirisha R, Indu I, Valli RH, Sravani I, Raju VB, et al. Spanlastics as innovative drug delivery system. Int J Innov Res Technol. 2024;11(7):3290-5.
7. Imam SS. The future of non-invasive ways to treat cancer. Int J Pharm Sci Res. 2021;12(9):4684-96.
8. Shinde AK, Sufi B, Deolekar RS, Bihade VD, Kale AA. Review on niosome-a future of targeted drug delivery system. Int J Adv Res Sci Commun Technol. 2023;3(2):716-24.
9. Alwan LA, Abd Alhammid SN. A modern method for the delivery of nanovesicular drugs, spanlastics. IAR J Pharm. 2023;4(6):1-11.
10. Vindhya VS, Kamath KK, Jain SK, Shabaraya AR. Spanlastics: a modern formulation approach in drug delivery. Eur J Pharm Med Res. 2023;10(4):96-102.
11. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sin B. 2011;1(4):208-19.
12. Subramaniyan G, Rubina S, Ramana BV, Stanley AM, Srinivasan D. Nano-revolution in transdermal drug delivery: a bibliographic compilation of vesicular system. Int J Pharm Investig. 2024;14(2):317-26.
13. Alva NR, Vineetha K, Kamath KK. Exploring spanlastic: an advanced vesicular drug delivery system. Eur J Biomed Pharm Sci. 2024;11(6):420-7.
14. Mousa SAA, Qelliny MR, Ibrahem RA, Hadiya S, Sarhan HA, Mady FM. Spanlastics: a unique formulation strategy in the delivery of pharmaceuticals-carbapenems as a model. J Adv Biomed & Pharm Sci. 2024;7(4):117-25.
15. El Menshawe SF, Nafady MM, Aboud HM, Kharshoum RM, Elkelawy AMH, Hamad DS. Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway. Drug Deliv. 2019;26(1):1140-54.
16. Farghaly DA, Aboelwafa AA, Hamza MY, Mohamed MI. Topical delivery of fenoprofen calcium via elastic nano-vesicular spanlastics: optimization using experimental design and in vivo evaluation. AAPS Pharm Sci Tech. 2017;18(8):2898-909.
17. Kaur IP, Rana C, Singh M, Bhushan S, Singh H, Kakkar S. Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole. J Ocul Pharmacol Ther. 2012;28(5):484-96.
18. Singh S, Walia MK, Pryanka, Kumari A. Spanlastic advanced approach as nanovesicular drug delivery system. Int J Sci Dev Res. 2023;8(9):422-6.
19. Wasankar SR, Deshmukh AD, Ughade MA, Burghat RM, Gandech DP, Meghwani RR, et al., Liposome as a drug delivery system- A review. Res J Pharma Dosage Forms Tech. 2012;4(2):104-12.
20. Mallikarjun DP, Pooja VM, Rajarajan S, Baby B, Rao V. A systematic review on non-invasive drug delivery on spanlastics. Int J Novel Res Dev. 2024;9(5):317-29.
21. Kumar KA, Sathyanarayanam S, Gomathi J. Nano spanlastics; a new formulation approach in novel drug delivery system. Int J Res Trends Innov. 2024;9(6):559-68.
22. Karim KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al., Niosome: a future of targeted drug delivery systems. J Adv Pharm Tech Res. 2010;1(4):374-80.
23. Khan A, Varshney C, Chaudhary T, Singh B, Nagarajan K. Spanlastics: an innovative formulation strategy in pharmaceutical drug delivery. World J Pharm Res. 2023;12(20):219-34.
24. Ashutosh L, Suman R, Sidhyartha S, Altaf bhai S, Vandana YM. A novel drug delivery system: niosomes review. J Drug Deliv Ther. 2012;2(5):129-35.
25. Ibrahim MS, Elkady OA, Amer MA, Noshi SH. Exploiting response surface D-optimal design study for preparation and optimization of spanlastics loaded with miconazole nitrate as a model antifungal drug for topical application. J Pharm Innov. 2023;18:2402-18.
26. Abdelbari MA, El-mancy SS, Elshafeey AH, Abdelbary AA. Implementing spanlastics for improving the ocular delivery of clotrimazole: in vitro characterization, ex vivo permeability, microbiological assessment and in vivo safety study. Int J Nanomedicine. 2021;16:6249-61.
27. Sharma A, Pahwa S, Bhati S, Kudeshia P. Formulation and evaluation of dorzolamide spanlastics. Int J Pharm Sci & Res. 2020;11(8):3930-5.
28. Kakkar S, Kaur IP. Spanlastics-a novel nanovesicular carrier system for ocular delivery. Int J Pharm. 2011;413(1-2):202-10.
29. Badria F, Mazyed E. Formulation of nanospanlastics as a promising approach for improving the topical delivery of a natural leukotriene inhibitor (3-acetyl-11-keto-β-boswellic acid): statistical optimization, in vitro characterization, and ex vivo permeation study. Drug Des Devel Ther. 2020;14:3697-721.
30. Mohanta P, Pandey NK, Kapoor DN, Singh SK, Sarvi Y, Sharma P. Development of surfactant-based nanocarrier system for delivery of an antifungal drug. J Pharm Res. 2017;11(9):1153-8.
31. Almohamady HI, Mortagi Y, Gad S, Zaitone S, Alshaman R, Alattar A, et al., Spanlastic nano-vesicles: a novel approach to improve the dissolution, bioavailability, and pharmacokinetic behavior of famotidine. Pharmaceuticals. 2024;17(12):1-25.
32. Zaki RM, Ibrahim MA, Alshora DH, El Ela AESA. Formulation and evaluation of transdermal gel containing tacrolimus-loaded spanlastics: in vitro, ex vivo and in vivo studies. Polymers. 2022;14(8):1-15.
33. Badr-Eldin SM, Aldawsari HM, Alhakamy NA, Fahmy UA, Ahmed OAA, Neamatallah T, et al., Merging experimental design and nanotechnology for the development of optimized simvastatin spanlastics: a promising combined strategy for augmenting the suppression of various human cancer cells. Pharmaceutics. 2022;14(5):1-16.
34. Wagdi MA, Salama A, El-Liethy MA, Shalaby ES. Comparative study of niosomes and spanlastics as a promising approach for enhancing benzalkonium chloride topical wound healing: in-vitro and in-vivo studies. J Drug Deliv Sci Technol. 2023;84(5):1-35.
35. Ghozzy OM, Abdelghani GM, Elsabbagh HM. Formulation, characterization, and ex vivo skin permeation of caffeine loaded spanlastic nanovesicles. IOSR J Pharm. 2020;10(2):1-15.
36. Abdelmonem R, Abo El-Enin HA, Abdelkader G, Abdel-Hakeem M. Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. Drug Deliv. 2023;30(1):1-11.
37. Alharbi WS, Hareeri RH, Bazuhair M, Alfaleh MA, Alhakamy NA, Fahmy UA, et al., Spanlastics as a potential platform for enhancing the brain delivery of flibanserin: in vitro response-surface optimization and in vivo pharmacokinetics assessment. Pharmaceutics. 2022;14(12):1-16.
38. Salamah M, Budai-Szűcs M, Sipos B, Volk B, Katona G, Balogh GT, et al., Development and characterization of in situ gelling nasal cilostazol spanlastics. Gels. 2025;11(2):1-24.
39. Batur E, Özdemir S, Durgun ME, Özsoy Y. Vesicular drug delivery systems: promising approaches in ocular drug delivery. Pharmaceuticals. 2024;17(4):1-27.
40. Almutairy BK, Khafagy ES, Abu Lila AS. Development of carvedilol nanoformulation-loaded poloxamer-based in situ gel for the management of glaucoma. Gels. 2023;9(12):1-15.
41. Fahmy AM, El-Setouhy DA, Ibrahim AB, Habib BA, Tayel SA, Bayoumi NA. Penetration enhancer-containing spanlastics (PECSs) for transdermal delivery of haloperidol: in vitro characterization, ex vivo permeation, and in vivo biodistribution studies. Drug Deliv. 2018;25(1):12–22.
42. Alaaeldin E, Abou-Taleb HA, Mohamad SA, Elrehany M, Gaber SS, Mansour HF. Topical nano-vesicular spanlastics of celecoxib: enhanced anti-inflammatory effect and down-regulation of TNF-α, NF-кB and COX-2 in complete Freund’s adjuvant-induced arthritis model in rats. Int J Nanomedicine. 2021;16:133–145.
43. Almuqbil RM, Sreeharsha N, Nair AB. Formulation-by-design of efinaconazole spanlastic nanovesicles for transungual delivery using statistical risk management and multivariate analytical techniques. Pharmaceutics. 2022;14(7):1-19.
44. Gupta I, Adin SN, Rashid MA, Alhamhoom Y, Aqil M, Mujeeb M. Spanlastics as a potential approach for enhancing the nose-to-brain delivery of piperine: in vitro prospect and in vivo therapeutic efficacy for the management of epilepsy. Pharmaceutics. 2023;15(2):1-19.
45. Kamath KK, Vindhya VS, Shripathy D, Shabaraya AR. Development of spanlastics: nanovesicular drug delivery of oxiconazole nitrate. Int J of Pharm Sci. 2024;2(3):483-93.
46. Safhi AY, Naveen NR, Rolla KJ, Bhavani PD, Kurakula M, Hosny KM, et al., Enhancement of antifungal activity and transdermal delivery of 5-flucytosine via tailored spanlastic nanovesicles: statistical optimization, in-vitro characterization, and in-vivo biodistribution study. Front Pharmacol. 2023;14:1-13.
47. Seary H, Barakat EH, Raslan MA, Samy AM. Development, characterization, and optimization of repaglinide loaded spanlastics along with investigation of drug solubility in various media. Univ J Pharm Res. 2024;9(5):105-112.
48. Saleh A, Khalifa M, Shawky S, Bani-Ali A, Eassa H. Zolmitriptan intranasal spanlastics for enhanced migraine treatment; formulation parameters optimized via quality by design approach. Sci Pharm. 2021;89(2):1-10.
49. Elhabak M, Ibrahim S, Abouelatta SM. Topical delivery of L-ascorbic acid spanlastics for stability enhancement and treatment of UVB induced damaged skin. Drug Deliv. 2021;28(1):445-453.
50. Ibrahim SS, Abd-allah H. Spanlastic nanovesicles for enhanced ocular delivery of vanillic acid: design, in vitro characterization, and in vivo anti-inflammatory evaluation. Int J Pharm. 2022;625(1-2):122068.
51. Mohamed NW, Sabry SA, Mahdy MA, Faisal MM. Tailoring of spanlastics for promoting transdermal delivery of irbesartan: In vitro characterization, ex vivo permeation, and in vivo assessment. J Drug Deliv Sci Technol. 2024;100:106088.
52. Almutairy BK, Khafagy ES, Aldawsari MF, Alshetaili A, Alotaibi HF, Abu Lila AS. Spanlastic-laden nanogel as a plausible platform for dermal delivery of bimatoprost with superior cutaneous deposition and hair regrowth efficiency in androgenic alopecia. Int J Pharm X. 2024;7:136-41.